Structure-based methods for the prediction of drug metabolism

Expert Opinion on Drug Metabolism and Toxicology

Volumn 2, Issue 4, 2006, Pages 545-557

  Madden, Judith C ^a   Cronin, Mark T D ^a  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

Author keywords

Bioavailability; Biotransformation; Expert systems; Homology modelling; Metabolism; Pharmacokinetics; Prediction; QSAR; Quantitative structure activity relationship

Indexed keywords

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; HUMAN; METABOLITE; METHODOLOGY; NONHUMAN; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STRUCTURAL HOMOLOGY; ALGORITHM; COMPUTER SIMULATION; EXPERT SYSTEM; METABOLISM; PREDICTION AND FORECASTING; STRUCTURE ACTIVITY RELATION;

ANIMALIA;

DRUG;

ALGORITHMS; COMPUTER SIMULATION; EXPERT SYSTEMS; HUMANS; PHARMACEUTICAL PREPARATIONS; PREDICTIVE VALUE OF TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33747868711     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.2.4.545     Document Type: Review

References (89)

1. DUFFY JC: Prediction of pharmacokinetic parameters in drug design and toxicology. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):229-261.
2. EKINS S, WALLER CL, SWAAN PW, CRUCIANI G, WRIGHTON SA, WIKEL JH: Progress in predicting ADME parameters in silico. J. Pharmacol. Toxicol. Methods (2000) 44:251-272.
3. VAN DE WATERBEEMD H: High-throughput and in silico techniques in drug metabolism and pharmacokinetics. Curr. Opin Drug Disc. Devel. (2002) 5:33-43.
4. TURNER JV, MADDALENA DJ, CUTLER DJ: Pharmacokinetic parameter prediction from drug structure using artificial neural networks. Int. J. Pharmacol. (2004) 270:209-219.
5. DE GRAAF C, VERMEULEN NPE, FEENSTRA KA: Cytochrome P450 in silico: an integrative modeling approach. J. Med. Chem. (2005) 48:2725-2755. Expansive overview of the use of molecular modelling techniques to predict interactions with CYPs.
6. DE GROOT MJ, EKINS S: Pharmacophore modeling of cytochromes P450. Adv. Drug Del. Rev. (2002) 54:367-383.
7. DE GROOT MJ, KIRTON SB, SUTCLIFFE MJ: In silico methods for predicting ligand binding determinants of cytochromes P450. Curr. Topics Med. Chem. (2004) 4:1803-1824.
8. EKINS S, BOULANGER B, SWAAN PW, HUPCEY MAZ: Towards a new age of virtual ADME/TOX and multidimensional drug discovery. J. Comput. Aided Mol. Des. (2002) 16:381-401.
9. EKINS S: In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem. Soc. Trans. (2003) 31:611-614.
10. HANSCH C, LEO A, MEKAPATI SB, KURUP A: QSAR and ADME. Bioorg. Med. Chem. (2004) 12:3391-3400.
11. HANSCH C, MEKAPATI SB, KURUP A, VERMA RP: QSAR of cytochrome P450. Drug Metab. Rev. (2004) 36:105-156.
12. KULKARNI SA, ZHU J, BLECHINGER S: In silico techniques for the study and prediction of xenobiotic metabolism: a review. Xenobiotica (2005) 35:955-973. Useful overview of some expert systems, drawing comparisons and evaluating the methods.
13. LANGOWSKI J, LONG A: Computer systems for the prediction of xenobiotic metabolism. Adv. Drug Del. Rev. (2002) 54:407-415. Good description of the commercially available expert systems for the prediction of metabolism.
14. LEWIS DFV: Quantitative structure-activity relationships (QSARs) for substrates of human cytochromes P450CYP2 family enzymes. Toxicol. In Vitro (2004) 18:89-97.
15. LONG A, WALKER JD: Quantitative structure-activity relationships for predicting metabolism and modeling cytochrome P450 enzyme activities. Environ. Toxicol. Chem. (2003) 22:1894-1899.
16. MANKOWSKI DC, EKINS S: Prediction of human drug metabolizing enzyme induction. Curr. Drug Metab. (2003) 4:381-391.
17. NORINDER U: In silico modelling of ADMET - a minireview of work from 2000 to 2004. SAR QSAR Environ. Res. (2005) 16:1-11.
18. PAYNE MP: Computer-based methods for the prediction of chemical metabolism and biotransformation within biological organisms. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):205-227. Excellent recent review on all aspects of structure-based metabolism prediction.
19. RETTIE AE, JONES JP: Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Ann. Rev. Pharmacol. Toxicol. (2005) 45:477-494.
20. SIRAKI AG, CHEVALDINA T, MORIDANI MY, O'BRIEN PJ: Quantitative structure-toxicity relationships by accelerated cytotoxicity mechanism screening. Curr. Opin. Drug Disc. Devel. (2004) 7:118-125.
21. SMITH PA, SORICH MJ, LOW LSC, MCKINNON RA, MINERS JO: Towards integrated ADME prediction: past, present and future directions for modelling metabolism by UDP-glucuronosyltransferees. J. Mol. Graphics Mod. (2004) 22:507-517.
22. TESTA B, CRUCIANI G: Structure-metabolism relations and the challenge of predicting biotransformation. In: Pharmacokinetic Optimization in Drug Research: Biological, Physicochemical, and Computational Strategies. B Testa, H van de Waterbeemd, G Folkers, R Guy (Eds), Wiley-VCH, Weinheim, Germany (2001):65-84. Useful review of QSAR in metabolism and general principles.
23. VAN DE WATERBEEMD H, GIFFORD E: ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. (2003) 2:192-204. A good starting point for information on the issues of metabolism and its assessment in drug discovery.
24. FRANK R, HARGREAVES R: Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. (2003) 2:566-580.
25. SUGIYAMA Y: Druggability: selecting optimised drug candidates. Drug Discov. Today (2005) 10:1577-1579.
26. POULIN P, KRISHNAN K: Molecular structure-based prediction of the toxicokinetics of inhaled vapors in humans. Int. J. Toxicol. (1999) 18:7-18.
27. CRONIN MTD: Toxicological information for use in predictive modeling: quality, sources and databases. In: Predictive Toxicology. C Helma (Ed.), Taylor & Francis, Boca Raton, FL, USA (2005):93-133.
28. BORODINA Y, SADYM A, FILIMONOV D, BLINOVA V, DMITRIEV A, POROIKOV V: Predicting biotransformation potential from molecular structure. J. Chem. Inf. Comp. Sci. (2003) 43:1636-1646.
29. KOROLEV D, BALAKIN KV, NIKOLSKY Y et al.: Modeling of human cytochrome P450-mediated drug metabolism using unsupervised machine learning approach. J. Med. Chem. (2003) 46:3631-3643.
30. MANGA N, DUFFY JC, ROWE PH, CRONIN MTD: A hierarchical QSAR model for urinary excretion of drugs in humans as a predictive tool for biotransformation. QSAR Comb. Sci. (2003) 22:263-273.
31. LEWIS DFV: COMPACT: a structural approach to the modelling of cytochromes P450 and their interactions with xenobiotics. J. Chem. Technol. Biotechnol. (2001) 76:237-244.
32. GALLIANI G, RINDONE B, DAGNINO G, SALMONA M: Structure-reactivity relationships in the microsomal oxidation of tertiary amines. Eur. J. Drug Metab. Pharmacokinet. (1984) 9:289-293.
33. NETZEVA TI, WORTH AP, ALDENBERG T et al.: Current status of methods for defining the applicability domain of (quantitative) structure-activity relationships. The report and recommendations of ECVAM Workshop 52. Altern. Lab. Anim. (2005) 33:155-173.
34. DURRER A, WALTHER B, RACCIATTI A, BOSS G, TESTA B: Structure-metabolism relationships in the hydrolysis of nicotinate esters by rat liver and brain subcellular fractions. Pharm. Res. (1991) 8:832-839.
35. LEWIS DFV, LAKE BG, DICKINS M: Quantitative structure-activity relationships (QSARs) in CYP3A4 inhibitors: the importance of lipophilic character and hydrogen bonding. J. Enz. Inhib. Med. Chem. (2006) 21:127-132.
36. MULHOLLAND AJ: Modelling enzyme reaction mechanisms, specificity and catalysis. Drug Disc. Today (2005) 10:1393-1402.
37. GAO JL, TRUHLAR DG: Quantum mechanical methods for enzyme kinetics. Ann. Rev. Phys. Chem. (2002) 53:467-505.
38. IOANNIDES C, LEWIS DFV: Cytochromes P450 in the bioactivation of chemicals. Curr. Topics Med. Chem. (2004) 4:1767-1788.
39. BUCHWALD P, BODOR N: Quantitative structure-metabolism relationships: steric and nonsteric effects in the enzymatic hydrolysis of non-congener carboxylic esters. J. Med. Chem. (1999) 42:5160-5168.
40. bind) for human P450 substrates. Curr. Drug Metab. (2003) 4:331-340.
41. LIVINGSTONE DJ: Building QSAR models: a practical guide. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):151-170.
42. HASHIDA M: In silico prediction of pharmacokinetic properties. Yakugaku Zassh - J. Pharm. Soc. Japan (2005) 125:853-861.
43. SORICH MJ, MINERS JO, MCKINNON RA, WINKLER DA, BURDEN FR, SMITH PA: Comparison of linear and nonlinear classification algorithms for the prediction of drug and chemical metabolism by human UDP-glucuronosyltransferase isoforms. J. Chem. Inf. Comp. Sci. (2003) 43:2019-2024.
44. KRIEGL JM, ARNHOLD T, BECK B, FOX T: Prediction of human cytochrome P450 inhibition using support vector machines. QSAR Comb. Sci. (2005) 24:491-502.
45. YAP CW, CHEN YZ: Prediction of cytochrome P450 3A4, 2D6 and 2C9 inhibitors and substrates by using support vector machines. J. Chem. Inf. Model. (2005) 45:982-992.
46. SHEN M, XIAO YD, GOLBRAIKH A, GOMBAR VK, TROPSHA A: Development and validation of k-nearest-neighbor QSPR models of metabolic stability of drug candidates. J. Med. Chem. (2003) 46:3013-3020.
47. BENDER A, GLEN RC: Molecular similarity: a key technique in molecular informatics. Org. Biomol. Chem. (2004) 2:3204-3218.
48. EKlNS S, DE GROOT MJ, JONES JP: Pharmacophore and three-dimensional quantitative structure-activity relationship methods for modeling cytochrome P450 active sites. Drug Metab. Dispos. (2001) 29:936-944. An excellent review of pharmacophores and modelling methods for cytochrome P450.
49. EKINS S, BRAVI G, BINKLEY S et al.: Three- and four-dimensional-quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2C9 inhibitors. Drug Metab. Dispos. (2000) 28:994-1002.
50. EKINS S, BRAVI G, BINKLEY S et al.: Three- and four-dimensional-quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors. Pharmacogenetics (1999) 9:477-489.
51. LOCUSON CW, WAHLSTROM JL: Three-dimensional quantitative structure-activity relationship analysis of cytochromes P450: effect of incorporating higher-affinity ligands and potential new applications. Drug Metab. Dispos. (2005) 33:873-878.
52. KORHÔNEN LE, RAHNASTO M, MAHONEN NJ: Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J. Med. Chem. (2005) 48:3808-3815.
53. HAJI-MOMENIAN S, RIEGER JM, MACDONALD TL, BROWN ML: Comparative molecular field analysis and QSAR on substrates binding to cytochrome P450 2D6. Bioorg. Med. Chem. (2003) 11:5545-5554.
54. SHARMA V, DUFFEL MW: A comparative molecular field analysis-based approach to prediction of sulfotransferase catalytic specificity. Phase II Conjugation Enz. Transport Sys. (2005) 400:249-270.
55. BUJNICKI JM: Protein-structure prediction by recombination of fragments. Chembiochem (2006) 7:19-27.
56. LEWIS DFV, ITO Y, GOLDFARB PS: Cytochrome P450 structures and their substrate interactions. Drug Devel. Res. (2005) 66:19-24.
57. ZAMORA I, AFZELIUS L, CRUCIANI G: Predicting drug metabolism: a site of metabolism prediction tool applied to the cytochrome P450 2C9. J. Med. Chem. (2003) 46:2313-2324.
58. KEMP CA, FLANAGAN JU, VAN ELDIK AJ et al.: Validation of model of cytochrome P450 2D6: an in silico tool for predicting metabolism and inhibition. J. Med. Chem. (2004) 47:5340-5346.
59. COMBES RD, RODFORD RA: The use of expert systems for toxicity prediction: illustration with reference to the DEREK system. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):193-204.
60. COECKE S, AHR H, BLAAUBOER BJ et al.: Metabolism: a bottleneck in in vitro toxicological test development. The report and recommendations of ECVAM Workshop 54. Altern. Lab. Anim. (2006) 34:49-84. Excellent overview of the state-of-the-art in metabolism, with a strong emphasis on in vitro techniques.
61. BOOBIS A, GUNDERT-REMY U, KREMERS P, MACHERAS P, PELKONEN O: In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. Eur. J. Pharm. Sci. (2002) 17:183-193.
62. BANIK GM: In silico ADME-Tox prediction: the more the merrier. Curr. Drug. Disc. (2004):31-34.
63. KLOPMAN G, DIMAYUGA M, TALAFOUS J: META I. A program for the evaluation of metabolic transformation of chemicals. J. Chemt. Inf. Comput. Sci. (1994) 34:1320-1325.
64. KLOPMAN G, TU M, TALAFOUS J: META 3. A genetic algorithm for metabolic transform priorities optimization. J. Chem. Inf. Comput. Sci. (1997) 37:329-334.
65. TALAFOUS J, SAYRE LM, MIEYAL JJ, KLOPMAN G: META 2. A dictionary model of mammalian xenobiotic metabolism. J. Chem. Inf. Comput. Sci. (1994) 34:1326-1333.
66. DARVAS F: MetabolExpert, an expert system for predicting metabolism of substances. In: QSAR in Environmental Toxicology. KLE Kaiser (Ed.), Reidel, Dordrecht, The Netherlands (1987):71-81.
67. DARVAS F: Predicting metabolic pathways by logic programming. J. Mol. Graph. (1988) 6:80-86.
68. BUTTON WG, JUDSON PN, LONG A, VESSEY JD: Using absolute and relative reasoning in the prediction of the potential metabolism of xenobiotics. J. Chem. Inf. Comp. Sci. (2003) 43:1371-1377.
69. GREENE N, JUDSON PN, LANGOWSKI JJ, MARCHANT CA: Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ. Res. (1999) 10:299-314.
70. TESTA B, BALMAT AL, LONG A, JUDSON P: Predicting drug metabolism - an evaluation of the expert system METEOR. Chem. Biodivers. (2005) 2:872-885.
71. CRUCIANI G, CAROSATI E, DE BOECK B et al.: MetaSite: understanding metabolism in human cytochromes from the perspective of the chemist. J. Med. Chem. (2005) 48:6970-6979.
72. EKINS S, KIRILLOV E, RAKHMATULIN EA, NIKOLSKAYA T: A novel method for visualizing nuclear hormone receptor networks relevant to drug metabolism. Drug Metab. Dispos. (2005) 33:474-481.
73. EKINS S, ANDREYEV S, RYABOV A et al.: Computational prediction of human drug metabolism. Expert Opin. Drug Metab. Toxicol. (2005) 1:303-324.
74. EKINS S, ANDREYEV S, RYABOV A et al.: A combined approach to drug metabolism and toxicity assessment. Drug Metab. Dispos. (2006) 34:495-503.
75. MEKENYAN OG, DIMITROV SD, PAVLOV TS, VEITH GD: A systematic approach to simulating metabolism in computational toxicology. I. The TIMES heuristic modelling framework. Curr. Pharm. Des. (2004) 10:1273-1293.
76. MEKENYAN O, DIMITROV S, DIMITROV N et al.: Metabolic activation of chemicals: in silico simulation. SAR QSAR Environ. Res. (2006) 17:107-120.
77. CALDWELL GW, YAN ZY: Screening for reactive intermediates and toxicity assessment in drug discovery. Curr. Opin Drug Disc. Devel. (2006) 9:47-60.
78. BUGRIM A, NIKOLSKAYA T, NIKOLSKY Y: Early prediction of drug metabolism and toxicity: systems biology approach and modeling. Drug Disc. Today (2004) 9:127-135.
79. http://mdl.com/products/predictive/metaboli te/index.jsp MDL Metabolite Homepage (2006).
80. http://www.accelrys.com/products/chem_dat abases/databases/metabolism. html Accelrys Metabolism Homepage (2006).
81. http://www.accelrys.com/products/catalyst/ Catalyst Home Page (2006).
82. http://www.tripos.com/index.php?family=mo dules,SimplePage,&page= sybyl_qsar_with_ comfa&s=0 QSAR with CoMFA (2006).
83. http://www.knowitall.com
84. http://www.multicase.com/products/prod051 .htm
85. http://www.compudrug.com/
86. http://www.lhasalimited.org/index.php?cat =2&sub_cat=68#
87. http://www.moldiscovery.com/soft_metasite. php
88. http://www.genego.com/about/products.sht ml#metadrug
89. http://www.oasis-lmc.org/?section=software& swid=4